RxDoctor Payments Data

Deneen Pelletier, MD

Internal Medicine · Cambridge, MANPI 1770571671

Payments from drug & device makers

$1,535in general payments, 2019–2025

Across 81 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$221
  • Amgen$147
  • Boehringer Ingelheim$147
  • AstraZeneca$122
  • Takeda Pharmaceuticals U.S.A., Inc.$101
  • Johnson & Johnson$83
  • plus $714 from 16 others

What the payments were for

  • Food & beverage$1,535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,535 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$178,103
Medicare patients
361
Services billed
2,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$88,813
TrulicityDulaglutide35$59,364
XareltoRivaroxaban26$32,074
MyrbetriqMirabegron31$23,426
LinzessLinaclotide26$17,903
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,667
FarxigaDapagliflozin Propanediol13$13,450
Estradiol86$10,986
Breo ElliptaFluticasone/Vilanterol24$9,646
Olmesartan Medoxomil218$9,449
Rosuvastatin Calcium254$8,157
JardianceEmpagliflozin11$7,583
Atorvastatin Calcium436$7,026
Metoprolol Succinate267$6,807
YuvafemEstradiol33$6,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$221$88,81373 claims
Lilly USA, LLCTrulicity$24$59,36435 claims
Johnson & JohnsonXarelto$83$32,07426 claims
GSKTrelegy Ellipta, Breo Ellipta$47$24,31340 claims
Astellas Pharma US IncMyrbetriq$42$23,42631 claims
AbbVieLinzess, Synthroid$47$19,26468 claims
AstraZenecaFarxiga$122$13,45013 claims
Boehringer IngelheimJardiance$147$7,58311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →